Quick Take
CureVac B.V. (CVAC) has filed to raise $100 million in an IPO of its common shares, according to an F-1 registration statement.
The firm is developing a wide range of treatments, vaccines and therapies based on messenger RNA technologies.
CVAC has developed extensive collaborations with major pharma firms and top tier research organizations.
I’ll provide a final opinion when we learn more about the IPO from management.
Company & Technology
Tubingen, Germany-based CureVac was founded to create mRNA-mediated treatment options for cancers, viral diseases including Covid-19 and gene editing-based protein